Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)
Completed
- Conditions
- Hypertension
- Interventions
- Drug: MicardisPlus®
- Registration Number
- NCT02243566
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The purpose of the study was to examine the effect of six- to eight-week treatment with MicardisPlus® on blood pressure and the effect of patient self-monitoring on blood pressure control. In addition, the post-marketing surveillance study offered the possibility to obtain information about the influence on different laboratory parameters during treatment with MicardisPlus® from an unselected patient group under office conditions
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2707
Inclusion Criteria
- Age > 18 years
- Hypertension
Read More
Exclusion Criteria
- Age < 18 years
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Essential hypertension MicardisPlus® -
- Primary Outcome Measures
Name Time Method Changes in morning blood pressure (systolic and diastolic) Pre-dose, up to 8 weeks after start of treatment Changes from baseline in laboratory values Pre-dose, up to 8 weeks after start of treatment Investigator assessment of efficacy on a 5-point scale Up to 8 weeks after start of treatment Investigator assessment of tolerability on a 5-point scale Up to 8 weeks after start of treatment Number of patients with adverse events Up to 8 weeks Investigator assessment of influence on metabolism on a 3-point scale Up to 8 weeks after start of treatment
- Secondary Outcome Measures
Name Time Method